Of note, EZH2 inhibitors reversed resistance to THZ531 by competitive inhibition of MDR1 and, in combination with THZ531, synergistically inhibited MCL and DLBCL growth in vitro. We also identified de novo and established acquired THZ531-resistant lymphoma cells conferred by over-activation of the MEK-ERK and PI3K-AKT-mTOR pathways and upregulation of multidrug resistance-1 (MDR1) protein. By implementing pharmacogenomics and a cell-based drug screen, we found that THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro. Here, we report that both MCL and DLBCL are exquisitely sensitive to transcription-targeting drugs, in particular THZ531, a covalent inhibitor of cyclin-dependent kinase 12 (CDK12). Identification of novel targets and therapeutic strategies for these diseases represents an urgent need. J Dermatol Res Ther.Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Anti-Androgen Therapy in Female Adult Acne. Identification and management of vulval problems of the postmenopausal woman – Tips and tricks. A Spring, D Griffiths, D Nirmal, J Gao, N Marrouche, A Skellett.Planning slow Mohs excision margins for lentigo maligna: a retrospective non-randomised cohort study comparing reflectance confocal microscopy margin mapping versus visual inspection with dermoscopy. J Gao, J Garioch, M Fadhil, E Tan, S Shah, M Moncrief.Occupational dermatoses during the second COVID-19 pandemic wave: a UK prospective study of 805 healthcare workers. J Gao, R Goiriz, S Rajpopat, P Goldsmith.Treatment of Skin Disease: Comprehensive Therapeutic Strategies. J Gao, M Rustin “Follicular Mucinosis” in M Lebwohl, W Heyman, J Berth- Jones, I Coulson (eds).She believes in keeping up to date and bringing scientific excellence to her work to achieve the best results.ĭr Mia Jing Gao is well published and some examples include the following publications: She is part of an expert group developing national guidelines on skin cancer management. She is active in research and regularly attends conferences and presents her work nationally and internationally. Dr Mia uses a holistic and personalised approach for all her patients. She ranked second nationally for competitive entry to dermatology specialist training and completed her dermatology training at expert centres including the Royal Free and Royal London Hospitals.Īs an experienced dermatology surgeon, Dr Mia has can perform cryotherapy, skin biopsies, curettage and skin excisions, as well as removal of benign lesions such as cysts, skin tags and warts. She studied clinical medicine at University College London and graduated with distinction amongst numerous other prizes. She studied medicine at University of Cambridge, achieving a Masters in Physiology and Development. Her main areas of interest include early detection of skin cancer, skin surgery, hair conditions, acne and general dermatology such as eczema, psoriasis and pigmentary disorders. She is the Skin Cancer Lead at Royal Free, one of the largest skin cancer services in England. She is an NHS consultant at the internationally renowned Royal Free Hospital in London. Dr Mia Jing Gao MBBS MA (Cantab) MRCP(UK) is a Consultant Dermatologist at OneWelbeck who consults on all skin and hair conditions.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |